Abstract: Multiple Myeloma is the second leading hematologic cancer in the United States with approximately 20,000 new cases diagnosedeachyear
Introduction

The proteasome complex
Normal cellular homeostasis requires an active processforproteindegradation.Overeightypercent ofcellularproteinsaredegradedbyaspecialorganelle known as the proteasome.The 26S proteasome complex is made up of several proteins organized in a conical structure of 4 rings containing three activesites;knownasthechymotrypsin-like(CT-L), caspase-like (C-L) and trypsin-like (T-L) catalytic sites( Fig.1 ).
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Proteinsaredesignatedforproteasome degradation by attachment of ubiquitin moieties to lysineresidues.Theseubiquitinstructuresarerecognized by proteasome complexes and they facilitate degradation.Proteasomeinhibitors,likebortezomib, specifically block the chymotryptic enzymatic site and thus prevent protein turnover. The build-up of cellular proteins or perhaps "debris" causes many changes within the cell that eventually results in apoptosis. In vitro studies has shown more apoptosis or an enhanced sensitivity to proteasome inhibition in cancer cells versus normal cells. 2, 3 However, the actual mechanism of this enhanced activity and the mechanismofapoptosisremainsunknown.
Preclinical studies
Manyinvestigatorshaveshownthatproteasomeinhibitionaffectsthetranscriptionfactornuclearfactor-κB (NFκB).NFκBstimulatestheproductionofgrowth stimulatory cytokines, induces cell cycle proteins, and enhances anti-apoptotic regulators. An overactive NFκB contributes to the pathogenesis of many cancers,includingmyeloma.TheactivityofNFκB is closelyregulatedbytheinhibitoryprotein-κB(IκB). IκB binds to NFκB, trapping NFκB in the cytosol and preventing NFκB induced DNA transcription. Under normal homeostasis and during cellular stress, IκB is degraded by the proteasome, thus promoting NFκB activity. Proteasome inhibition(PI) results in the opposite effect; intracellular IκB levels rise and NFκBactivityisdiminished. 4, 5 Severalin vitrostudiesinmyelomacelllineshave failed to demonstrate NFκB stabilization following exposuretoPI,andthusadditionalmechanismsmust beinvolved. 6, 7 Publishedstudieshavedescribedactivationandinactivationofmanycellularprocessesand overorunderexpressionofseveralimportantregulatory proteins following PI. For example, myeloma celllinesexposedtobortezomibproducelowerlevels of stimulatory cytokines includingTNF-a and IL-6, anddemonstratediminishedlevelsofimportantcell adhesion molecules making MM cells more prone to apoptosis. 8 Gene expression and proteomic studieshaveconfirmedthatbortezomibsuppressesmoleculesinvolvedinDNArepair,thuslimitingtheability ofMMcellstorepairdamagecausedbyconventional chemotherapy.
3 PIalsoeffectsthecyclecellthrough stabilizationofthetumorsuppressorproteinp53and thecheckpointproteinsp21andp27.
9 Additional proteins directly responsible for apoptosis may also be affected by PI. Data suggest that Bax and Bak are upregulated following exposure to bortezomib, and anti-apoptoticproteins,includingBcl-2andcaspase inhibitors, are suppressed.
Another emerging mechanism for PI-induced apoptosisisthroughadirecteffectontheunfoldedproteinresponse(UPR).Myelomacellsare professional "factories"forprotein(i.e.immunoglobulin)productionwhichrequiresahighlydevelopedendoplasmic reticulum(ER). Proper protein translationand foldingoccursintheERandthisiscloselyregulatedby the UPR. The UPR can transmit information to the nucleusabouttheproteinfoldingstatus(i.e.health)of theERandcaninduceeitherapoptosisorenhanced protein production. Misfolded or unfolded proteins arerecognizedbytheERqualitycontrolsystemsand areactivelysentoutoftheERtotheproteasomefor degradation. Data suggest that bortezomib can promoteapro-apoptoticresponseviatheUPRbyblocking degradation of misfolded proteins and allowing proteinstoaccumulateintheER. [12] [13] [14] Bortezomib has been tested in a wide range of human MM cell lines, primary human MM cells and murine xenograft models showing potent dosedependentanti-tumorresponses.Similarmodelshave shownsynergywithradiation,avarietyofchemotherapeutic agents, immune modulatory drugs (Imids), histone deacetylase inhibitors and other proteasome inhibitors. 15, 16 The marked activity of bortezomib in preclinicalstudiesprovidedstrongsupportforinitiating clinical studies in patients with myeloma. 
Bortezomib combinations
FollowingtheSUMMITandAPEXtrials, numerous studies have evaluated bortezomib in combination with a variety of biologic and chemotherapeutic agents,bothassalvagetherapyandinthefront-line setting. Many of these combinations were based on pre-clinical models showing synergy and enhanced activation of pathways for cell death. Due to the limitsofthisreview,onlythehighlightsofthemost influentialclinicaltrialswillbedescribed.
Bortezomib with alkylators
Since the early 1960's, melphalan and prednisone (MP)hasbeenthemainstayoftreatmentforelderly patientswithmyeloma.Inaddition,preclinicalstudies showed synergy for bortezomib with alkylators consequently, there was great interest in combining theseagents.Mateosetal,werethefirsttoreporta front-linePhaseI/IItrialusingbortezomib,melphalan andprednisone(VMP).Inolder,transplant-ineligible patients, VMP produced an overall response rate of 89%, including 32% CRs. 25 The median time to progressionwas27.2monthsand85%oftheseelderly patients were alive at 3 years. 26 These positive resultspromotedalarge,multi-national,randomized PhaseIII(VISTA)trialcomparingVMP× 9 cycles to standard MP × 9 cycles in elderly patients with newly diagnosedMM.Therandomizedstudyconfirmedthe positiveresultsseeninPhaseII.VMPprovidedmuch moreanti-myelomaactivity(ORR71%vs.35%;CR 30%vs.4%),andtimetoprogressionstronglyfavored VMP(24monthsversus16.6months;P ,0.001).
27
Amorerecentupdatehasconfirmedanoverallsurvival advantage in those receivingVMP versus MP (35%reducedriskofdeath;HR,0.653;P ,0.001).
28
ThistrialledtoFDAapprovalforbortezomibasfrontlinetherapyintheUSandapprovalbytheEMEAin Europe.VMPisnowconsideredastandardregimen for non-transplant candidates with newly diagnosed multiple myeloma.
More recently, Mateos et al, compared front-line VMP to bortezomib, thalidomide and prednisone (VTP)inelderlypatientswithMM.Patientsreceived 9cyclesofVMPorVTPandthenasecondrandomiza-tion compared maintenance withVT versusVP.The results, presented at theAmerican Society of Hematology meetings in December 2009, showed similar overall and complete response rates forVMP vs. VTP(ORR80%vs.81%,CR32%vs.31%).Afterthe first six weeks of therapy, both groups subsequently receivedbortezomibweeklyratherthantwiceweekly. The reduced frequency of bortezomib appeared to improve tolerability with less neuropathy and without compromising efficacy. The VTP arm was associated with increased cardiac events. Both regimens ofmaintenance(VTandVP)werewelltoleratedand responses improved following maintenance therapy (higherORR,VGPRandCRrates).TheauthorsconcludedthatbothVMPandVTPwereveryactiveinthis elderlypopulationandthatfurtherstudiesevaluating maintenancetherapywithbortezomibarewarranted.
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Since significant synergy had been demonstrated with bortezomib and melphalan (i.e. an alkylator), studies evaluating the combination of cyclophosphamide,bortezomibanddexamethasone(CyBorD)were initiated.Anadvantageforcytoxanisthelackofstem celltoxicity,thusallowinguseasfront-linetherapyin young transplant eligible subjects. In a Mayo Clinic study,bortezomib1.3mg/m anddexamethasone40mgorallyondays1-4,9-12 and17-20ona28-daycycle.Thestudyreportedan impressiveORRof88%,with61%achievingVGPR and39%CR/nCRfollowing4cyclesoftherapy.All patientsundergoingstemcellharvesthadasuccessfulcollectionandallpatientsreceivingtransplantation engraftedasexpected.
30
Toxicitywassignificant,promoting Reeder and colleagues to modified the regimen (Mod-CyBorD) by changing the bortezomib to 1.5mg/m 2 givenweekly(D1, 8, 15, 22) ,anddecreasingthedexamethasonetoonceweeklyafterthefirst twocycles.Theresultsdemonstratedsimilarefficacy (ORR 93%, CR/nCR 43%) but marked improved tolerability. The incidence of grade $3 thrombocytopenia, neutropenia and peripheral neuropathy decreased from 21% to 0%, 12% to 7% and 6% to 0%, respectively.
31
The authors suggested that modCyBorDisnowtheirpreferredinductionregimenfor younger transplant eligible patients.
Bortezomib with anthracyclines
Trials investigating the combination of bortezomib and doxorubicin were initiated based on preclinical data suggesting that doxorubicin resistance was, in part,duetoactivationofNFκB.
32
EarlyPhaseI/IItrials were promising, 33, 34 propelling Orlowski and colleaguestoperformalargerandomized,multi-center Phase III trial comparing bortezomib alone versus bortezomib plus pegylated liposomal doxorubicin (30mg/m 2 givenonDay4)inpatientswithrelapse andrefractoryMM.Thestudyenrolled646patients and showed improved time to progression (9.3 versus6.6months,P  0.01),improveddurationof response (10.2 versus 7 months, P  0.01) and an overallsurvivaladvantageat15months(76%versus 65%,P =0.03)forcombinationtherapy. 35, 36 Based on thistrial,theFDAapprovedthecombinationofbortezomibandpegylatedliposomaldoxorubicinasfirst salvageinbortezomibnaïvepatientsin2007.Since then,manyfront-linestudiesinvestigatingcombinationsofbortezomib,doxorubicinanddexamethasone havebeenreported.Ingeneral,ORRsof.90%and CRsof.20%havebeennoted. [37] [38] [39] Thesecombinationshavebeenusedwithsuccessinbothtransplant eligible and in-eligible patients. 40 One interesting finding from Olowski's randomized trial was that single nucleotide polymorphisms in the multidrug resistance protein 1 and in P-glycoprotein 1 genes were predictive of treatment outcomes in patients with advanced multiple myeloma. The authors propose that this genetic data could be used in future studiestohelpidentifypatientsmostlikelytobenefit frombortezomibandanthracycline-basedtherapy. 41 
Bortezomib and imids
The immune modulatory drugs (Imids; thalidomide an lenalidomide) have played a significant role in the treatment of MM over the past decade. Consequently,therehasbeengreatinterestforcombining, arguably,thetwomostpotentclassesofanti-myeloma drugs, imids and proteasome inhibitors. Alexanian andcolleaguesatMDAndersonCancerCenterwere thefirsttoreportafront-linePhaseIIstudycombining bortezomib, thalidomide and dexamethasone (VTD).Atotalof38patientsreceivedupto3cycles oftherapy(bortezomib1.3mg/m 2 × 4,Thalidomide 100-200 mg daily, dexamethasone 20 mg/m 2 day 1-4, 9-12, 17-20; every 28 days). Rapid responses were achieved with an ORR of 87% and 6 patients achievingCR(16%). 42 Severalgroupshavereported equallyimpressiveresultswithVTDbothinelderly patients and in transplant eligible patients.
43,44
In vitro, lenalidomide is much more potent than thalidomide and shows improved synergy with bortezomib.Consequently,thecombinationwasexpected toshowgreaterclinicalactivity.RichardsonetalperformedaPhaseIcombininglenalidomideandbortezomib with subsequent addition of dexamethasone (RVD) in patients with relapse and refractory MM. In 38 heavily pretreated patients, (median 5 prior therapies), the ORR was 39%. 45 Richardson also performed a front-line Phase I/II RVD clinical trial involving 66 patients. 
Bortezomib with novel agents
There are numerous novel agents under investigation for the treatment of relapse myeloma. Many of these have been rationallycombined with bortezomibduetooverlappingorsynergisticactivities. Histone deacetylase inhibitors, which block the autophagypathwayanddecreaseacells'abilityto degrade mis-folded proteins demonstrate significant in vitrosynergywithbortezomib.InaPhaseI studyusingvorinostatwithstandardbortezomib(4 dosesevery3weeks),theMTDforvorinostatwas 400mgdailyfor8days.Twenty-threeheavilypretreatedpatients(median7priortreatments)received treatment and 41% achieved partial remission. 52 SeveralotherHDACinhibitortrialsareunderway, testing many different schedules and combinationsofagents. 53, 54 Perifosineisaninhibitorofakt, a pro-survival protein kinase which partially acts by promoting NFκB.InaPhaseIItrial,perifosine plus bortezomib resulted in an ORR of approximately41%;32%intrulybortezomibrefractory. 
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Bortezomib with autologous transplantation
Clinicaltrialsincorporatingbortezomib-basedinductionpriortoautoSCThaveyieldedpromisingresults. In the IFM 2005/01 trial, 482 transplant-eligible patients ,65yearsofagewererandomizedtoreceive vincristine,adriamycinanddexamethasone(VAD)or bortezomib plus dexamethasone (VD) as induction, followed by a high dose melphalan-based autoSCT. VDinductionwassuperiortoVADacrossallresponse criteria, with higher rates of PR, very good partial response(VGPR),andCR/nearCR(nCr). 60 Inaddition,pre-transplantVDversusVADresultedinsuperiorresponseratespost-transplantandasignificantly higher two-year overall survival. In another phase IIItrialbytheItalianMyeloma NetworkGIMEMA, 480transplant-eligibleMMpatients,65yearsofage wererandomizedtothreecyclesofTDversusVTD. After three induction cycles, individuals in both groupsunderwentstemcellmobilizationfollowedby autoSCT.Overall,VTDledtosuperiorratesofPR, VGPR, and CR/nCR rates, as well as a significant two-year PFS benefit (90% vs. 80%). 44 These studiessuggestaroleforbortezomibasinductiontherapy pre-transplant,andacontinuedroleforautoSCT,with improvedCRratesfollowingtransplant,inthenovel drug era. At UCSF, transplant eligible patients are encouragedtoundergoautoSCT following induction therapy to enhance the remission.
Many centers are now investigating the use of bortezomibwithhigh-dosemelphalanaspreparative therapyforASCT.AlargeFrenchstudyhasconfirmed the safety of adding bortezomib (1 mg/m 2 on Day −6, −3, +1, +4) to high-dose melphalan (200 mg/m 2 on Day −2). In a matched control analysis, patients receiving melphalan + bortezomib were more likely toachieveCRversusthosereceivinghigh-dosemelphalanalone(36%versus11%). 61 Theseresultsneed to be confirmed in a large Phase III trial. However, emergingdatasuggestthatthesequenceofadministration may be important. Researchers from Emory Universityhavereportedthatbortezomibgivenonthe dayfollowinghigh-dosemelphalanisassociatedwith moreapoptoticmarrowplasmacellsthenifbortezomib isgivenbeforemelphalan. 62 Alternativedosingschedulesofbothbortezomibandmelphalanarealsobeing tested and the optimal regimen remains unclear. At the ASHmeetinglastyear,agroupfromtheNetherlands reported a trend towards less disease progression post-autologoustransplantforpatientsreceivingbortezomibmaintenancetherapyversusobservation(12% vs.6%;P =0.08). 63 Currently,therearenopublished randomizedtrialsinvestigatingbortezomibaspartof preparative therapy or for maintenance therapy with autologous transplantation. Additional studies are warrantedbeforethesepracticescanberecommended.
Overall,mostcombinationsutilizingbortezomibas frontlinetherapyhavedemonstratedORRofapproximately85%-95%withVGPRandCRseeninapproxi-mately40%-70%and25%-35%,respectively. 64 These remissions have occurred independent of age and regardlessofpoorriskfeatures.Thiswasunexpected, butthedatasuggestthatpatientswithwell-classified adverseprognosticfeaturesincludingabnormalkaryotype(del13,t(4,14),t(14,16),complexcytogenetics), high β2m,andhighLDHhavegenerallyresponded equallyaswellaspatientswithoutthesefeatures.One caveat may be the presence of gain of chromosome 1q21byinterphasefish.Changandcolleaguesdemonstratedshorterprogressionfreeandoverallsurvivalin cases with 1q21 gain. 65 Overall,mostexpertsrecommendincludingbortezomibaspartoffront-linetreatmentofallpatientswithadverseprognosticfeatures.
Safety
Wenowhaveover10yearsofclinicalexperiencewith bortezomib, and consequently the safety profile has beenwelldefined.Ingeneral,thisfirst-in-classproteasome inhibitor has been well tolerated but some patients willrequiredoseadjustment,delayordiscontinuation due to toxicity. The most common side effects have been infusional symptoms, asthenia, gastrointestinal symptoms, neuropathy and bone marrow suppression. Ofthese,neuropathyisthemostconcerningandmost likelytoimpactqualityoflife.Severetoxicityincluding death has been reported in ,3%ofpatients.Most adverseeffectsarereversibleandcanbealleviatedwith dose reductions and/or temporary delays in therapy. Thefollowingsectionswilldescribeindetailthesafety informationforbortezomibinpatientswithmyeloma.
infusion reactions and general toxicity
Infusional side effects including fever, chills and mild hypotension occur in ,10%ofpatients.These symptoms may be exacerbated by dehydration thus prompting the recommendation to give intravenous saline hydration just prior to bortezomib. Pyrexia can be controlled with acetaminophen administration and these symptoms are rarely dose limiting. Tumor lysis syndrome has been described (,2%) and patients with more severe symptoms following initiation of therapy should be evaluated for TLS. Allopurinol should be considered when initiating therapyinpatientswithadvanceddisease.Twoofthe mostcommonsymptomsassociatedwithbortezomib are fatigue and asthenia. These symptoms occur in approximately 15%-30% of patients and are dose limitinginaminorityofcases. 20, 27, 66 Gastrointestinal toxicity Gastrointestinaladverseeventshavebeenverycommon with bortezomib including nausea, vomiting, diarrhea,abdominalpainandconstipation.TheAPEX trialreportedanincidenceofnauseaanddiarrheaof 57%, constipation 42% and vomiting 35%. In the VISTAtrial,nauseaanddiarrheawaspresentin48% and 46% of patients, but severe, grade $3, symptoms were seen in only 4% and 8% respectively. 66 Most centers give a serotonin 5-HT3 antagonist as anti-nauseaprophylaxisandloperamidemaybeused as needed for diarrhea. There have been rare cases ofparalyticileus,thusanti-diarrhealsshouldbeused withcaution.Severeperipheralneuropathyisassociatedwithanincreasedriskforileus.
Cardiopulmonary toxicity
Most studies have described a low incidence of cardiac or pulmonary toxicity. Patients with new or worsening pulmonary or upper respiratory symptoms must be evaluated for an acute infection. The APEXtrialreportedpneumoniain7%ofbortezomib treated patients and other studies have described symptoms of cough and dyspnea in approximately 10%. 23, 27, 66 Bacterial and viral infections have been the most common causes for these symptoms however, idiopathic pulmonary infiltrates, pneumonitis, pulmonaryhypertension,andcongestiveheartfailure withdecreasedcardiacejectionfractionhaveallbeen described (,5% incidence). The randomized pegylated liposomal doxorubicin plus bortezomib trial reportedanincidenceofcardiomyopathyof3%inthe combinationarmversus2%withbortezomibalone. 35 Althoughinfrequent,cardiopulmonarysymptomscan occasionally be severe, requiring prompt evaluation andpossiblediscontinuationofbortezomibtherapy.
Skin toxicity
Skin reactions have been mild and have ranged between 5% and 24%. 20, 67 A maculopapular rash is most common but nodular lesions, generalized erythemaandedematousplaqueshaveallbeendescribed. Ingeneral,thepathologyhasshownvasculiticreactionsalthoughhypersensitivityreactionsandsweets syndromehavealsobeenreported. 68, 69 Therashmay recurwithre-treatmentandcorticosteroidshavebeen used with success for preventing these recurrences. Rarely, discontinuation of therapy is required either duetoseverehypersensitivityreactionorworsening/ recurring rash.
infectious complications
ThelargeAPEXtrialdemonstratedariskofherpes zoster reactivation of 13% although the incidence can bedecreased (3%) withthe use of prophylactic acyclovir. 70, 71 Viral and bacterial infections occur in 10%-15%, and most commonly cause pneumonia, bronchitis and nasopharyngitis. Other than herpes zoster,theinfectionriskdoesnotappearincreasedin MMpatientsreceivingbortezomibversusotherantimyelomatherapies.Despitethatmoderatetosevere lymphopenia is common with bortezomib, other immunocompromisedinfectionsarerare.
Marrow toxicity
Bonemarrowsuppressionisacommonsideeffectof bortezomibandoneofthemaincausesofdosereductionsanddelaysintherapy.InthelargeAPEXtrial, hematologic toxicity included grade $3 neutropenia in 14%,grade$3thrombocytopeniain30%andGr$ 3 anemia in 10%. 66 Similar patterns of marrow suppressionhavebeenseeninmostbortezomibclinical trials.Theneutropeniaandthrombocytopeniafollow a cyclical pattern with nadir counts occurring around day11-14ofatypical21-daycycle (Day1,4,8,11  dosing) .Thecountsuniformlyrecoverbythestartof the next cycle and cumulative marrow suppression has not been problematic. Presumably, the thrombocytopeniaisduetoinhibitionofplateletreleaserather thandirectmegakaryocytecytotoxicity.Thedegreeof thrombocytopeniafollowingbortezomibtherapycan oftenbecorrelatedtopre-treatmentplateletlevelsand diseaseburdeninthemarrow.Theuseofconcomitant marrow-toxicagentslikelenalidomide,melphalanor cyclophosphamide frequently causes more neutropenia and thrombocytopenia. 27 When making dose adjustmentsduetocytopeniasonemustconsiderthe diseasestatusofthepatientandthegoalsoftherapy. For example, one may accept a much lower platelet count before dose reduction in those patients with higher disease burden whereas a low platelet count in apatientinremissionmaydeserveadosereduction. Ageneralschemafordosereductionanddelaysbased onpre-treatmentplateletcountsandnadircountshas beenproposed (Fig.2) . ∧ large nerve fibers. 73, 74 A more complete physiologic andpathologicunderstandingofBIPNisneededso thatbettertherapeuticscanbedeveloped.
Neurologic toxicity
The clinical characteristics of BIPN are well described. The symptoms are more sensory (tingling,burning,numb)thanmotor,occurmoredistal than proximal and involve the feet and toes more thanthehandsandfingers.Symptomsoftenbegin withinthefirst1-2cycles,progressuntilcycle5-6 (ie,cumulativebortezomibdoseof30mg/m 2 )and thereafterremainstable.Patientswhoareneuropathy-freebycycle5-6tendtoavoidneuropathyalto-gether. Pain is less common but, can be debilitating and difficult to treat. Diminished or absent deep tendonreflexesarecommonandnerveconduction studiesshowlowamplitudeactionpotentials.The severityofBIPNhasbeendependentonanumber offactorsincludingbortezomibdoseandschedule, concomitant medical illness and prior exposure to other neuropathic agents. 75 Patientsreceivingbortezomib therapy need to be followed closely for BIPN so that appropriate dose adjustments can be made (Fig.3) . Pooleddatafrom256patientstreatedonthePhaseII CRESTandSUMMITtrialsdemonstratedthatBIPN wasoneofthemostcommonadverseeventsoccurring in 35% of enrolled patients.The majority of patient experiencedgrade1to2events(22%)whereasgrade 3and4eventswereless frequent(13%and0.4%).
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IntheAPEXtrial,theincidenceofBIPNwas44%ver-susonly9%inthedexamethasonetreatmentarm. 66 In theVISTAtrial,BIPNwasreportedmorefrequentlyin theVMPvs.MParm;44%overallwith14%grade1, 17%grade2,13%grade$3.
27 Surprisingly, the concomitant use of other agents, including thalidomide and lenalidomide, does not appear to affect BIPN. Trials using a reduced bortezomib dose or schedule (i.e.CRESTandmod-CyBorD)havebeenshownto decreasetheincidenceandseverityofBIPNandmay beappropriateinolderMMpatientsorthoseathighrisk for BIPN. 31, 76 Once severe BIPN occurs, bortezomibtherapymustbediscontinued.Arecentupdate fromtheVISTAtrialhasshownthat79%oftheBIPN eventsintheVMParmimprovedwithin1.9months and that 60% of events resolved completely after a median of 5.7 months.
28 Similar data was reported fromtheAPEXtrial. Forty-fourof87patients(51%) experiencing grade $2BIPN,showedimprovedneuropathywithamediantimetoimprovementofapproximately 3.5 months. Forty patients had resolution of BIPN,orareturntobaseline,and4hadimprovement without complete resolution. 66 Since not all patients withmoderatetosevereBIPNimproveovertime,our best strategy is with close monitoring, early detection
• Discontinue BORTEZ GRADE 4 (Sensory neuropathy that is disabling, or motor neuropathy that is life-threatening or leads to paralysis)
• Withhold BORTEZ until toxicity resolves 
Conclusions
Theproteasomeiscertainlyapotenttargetforanticancer therapy. Bortezomib, the first-in-class proteasome inhibitor, has demonstrated impressive anti-tumorresponsesinbothpreclinicalmodelsand clinical trials. Bortezomib is now one of the most common agents used as initial and salvage therapy for patients with myeloma. Overall response rates of.90%cannowberoutinelyachievedinpatients with newly diagnosed myeloma and survival has been extended. Further clinical studies are underway attempting to identify the optimal combinations of agentsanddurationoftreatment.Additionalstudies arecombiningbortezomibwithmelphalan-basedpreparative therapy for autologous transplantation, and testingtheroleofbortezomibasmaintenance therapy. Anewgenerationoftargetedtherapiesincludingakt inhibitors, histone deacetylase inhibitors, heat shock protein inhibitors, monoclonal antibodies and others are now undergoing preclinical an early clinical studies in combination with bortezomib.Although bortezomib has been well tolerated, common toxicities including gastrointestinal symptoms and peripheral neuropathyneedtobemonitoredclosely.Earlyintervention for those experiencing toxicity and further strategies for improving safety while maintaining efficacy are warranted. Second generation proteasome inhibitors including oral agents are currently underinvestigation.
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